Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug shows promise for Hard-to-Treat cancers

NCT ID NCT06107686

Disease control Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called YL202 in people with advanced solid tumors, including lung, breast, and head/neck cancers. The goal is to see if the drug can shrink tumors and control the disease. About 200 participants will receive the drug, and researchers will monitor safety and how well it works.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2023

Expected to finish

Nov 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Subjects who are aware of relevant trial information before the start of the trial, and voluntarily sign and date on the informed consent form (ICF). 2. Subjects aged from 18-75 (inclusive) years. 3. Histologically or cytologically confirmed at diagnosis of NSCLC/BC/HNSCC/other locally advanced or metastatic solid tumors including but not limited to colorectal cancer, HER2-positive gastric cancer, cervical cancer, ovarian cancer, etc.. 4. At least one extracranial measurable lesion according to RECIST 1.1. 5. Archived or fresh tumor tissue samples can be provided. 6. With Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0 or 1. 7. The function of organs and bone marrow meets the requirements within 7 days before the first dose. 8. Female subjects of childbearing potential must agree to adopt highly effective contraceptive measures from screening throughout the study period and within at least 6 months after the last dose of the investigational product. Male subjects must agree to adopt highly effective contraceptive measures from screening throughout the study period and within at least 6 months after the last dose of the investigational product. 9. With expected survival ≥ 3 months. 10. Be capable of and willing to comply with the visits and procedures stipulated in the study protocol. Exclusion Criteria: 1. With prior drug therapy targeting HER3 (including antibodies, antibody-drug conjugates \[ADCs\]), chimeric antigen receptor T-cell immunotherapy (CAR-T), and other drugs). 2. Previously intolerant to topoisomerase I inhibitors or ADC therapy composed of topoisomerase I inhibitors. 3. Are participating in another clinical study, unless it is an observational (non-interventional) clinical study or in the follow-up period of an interventional study. 4. The washout period from the previous anti-tumor therapy is insufficient before the first dose of the investigational product. 5. Patients who have received major surgery (excluding diagnostic surgery) within 4 weeks before the first dose of the investigational product or those who are expected to receive major surgery during the study. 6. Prior treatment with allogeneic bone marrow transplantation or solid organ transplantation. 7. Prior treatment with systemic steroids (prednisone \> 10 mg/day or equivalent) or other immunosuppressive treatment within 2 weeks before the first dose of the investigational product. 8. Patients who have received any live vaccine within 4 weeks before the first dose of the investigational product or those who plan to receive live vaccine during the study period. 9. With meningeal metastasis or cancerous meningitis. 10. With brain metastasis or spinal cord compression. 11. Patients with uncontrolled or clinically significant cardiovascular diseases. 12. Clinically significant complicated pulmonary disorders. 13. Patients diagnosed with Gilbert syndrome. 14. Those with uncontrolled effusion in the third space requiring repeated drainage. 15. With a medical history of gastrointestinal perforation and/or fistula within 6 months before the first dose, or with active gastric and duodenal ulcers, ulcerative colitis, or other gastrointestinal diseases that may lead to hemorrhage or perforation according to the investigator. 16. With serious infection before the first dose. 17. With known human immunodeficiency virus (HIV) infection. 18. With active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection. 19. With a medical history of any other primary malignancies within 5 years before the first dose of the investigational product. 20. Unrelieved toxicity of previous anti-tumor therapy. 21. With a history of severe hypersensitivity to inactive ingredients in the raw materials and drug product or other monoclonal antibodies. 22. Lactating women, or women who are confirmed pregnant via a pregnancy test within 3 days before the first dose. 23. With any diseases, medical conditions, organ system dysfunction, or social conditions that may interfere with the ability of subjects to sign the ICF, adversely affect the ability of subjects to cooperate and participate in the study, or affect the interpretation of study results, including but not limited to mental illness or substance/alcohol abuse, in the opinion of the investigator.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm cervical cancer colorectal cancer head and neck squamous cell carcinoma non-small cell lung carcinoma ovarian cancer Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer HNSCC Locally advanced or metastatic solid tumors NSCLC

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    82 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Affiliated Hospital of Jining Medical University

    NOT_YET_RECRUITING

    Jining, Shandong, China

  • Anhui Tumour Hospital

    RECRUITING

    Hefei, Anhui, China

  • Beijing Cancer hospital

    RECRUITING

    Beijing, Beijing Municipality, China

  • Beijing Tsinghua Chang Gung Hospital

    NOT_YET_RECRUITING

    Beijing, Beijing Municipality, China

  • China-Japan Union Hospital of Jilin University

    RECRUITING

    Changchun, Jilin, China

  • Chinese First Affiliated Hospital of Army Medical University of the People's Liberation Army

    NOT_YET_RECRUITING

    Chongqing, Chongqing Municipality, China

  • Chongqing University Affiliated Tumor Hospital

    RECRUITING

    Chongqing, Chongqing Municipality, China

    Contact Email: •••••@•••••

  • First Affiliated Hospital of Gannan Medical University

    NOT_YET_RECRUITING

    Ganzhou, Jiangxi, China

  • Fujian Tumor Hospital

    RECRUITING

    Fuzhou, Fujian, China

  • Fukuang General Hospital of Liaoning Health Industry Group

    NOT_YET_RECRUITING

    Fushun, Liaoning, 530021, China

  • Guangxi Medical University Affiliated Tumour Hospital

    RECRUITING

    Nanning, Guangxi, China

    Contact Email: •••••@•••••

  • Guangxi Medical University Cancer Hospital

    RECRUITING

    Nanning, Guangxi, 530021, China

  • Guilin Medical College Second Affiliated Hospital

    RECRUITING

    Guilin, Guangxi, China

  • Harbin Medical university cancer hospital

    RECRUITING

    Harbin, Heilongjiang, China

  • He'nan Cancer Hospital South Gate

    RECRUITING

    Zhengzhou, Henan, China

  • Henan Provincial Chest Hospital

    RECRUITING

    Zhengzhou, Henan, China

  • Hu'nan Province Cancer Hospital

    RECRUITING

    Changsha, Hunan, China

  • Huashan Hospital affiliated to Fudan University

    RECRUITING

    Shanghai, Shanghai Municipality, China

    Contact Email: •••••@•••••

  • Hubei Cancer Hospital

    RECRUITING

    Wuhan, Hubei, China

  • Hunan Provincial People's Hospital

    RECRUITING

    Changsha, Hunan, China

  • Jiangxi Cancer Hospital

    NOT_YET_RECRUITING

    Nanchang, Jiangxi, China

  • Jilin Provincial Cancer Hospital

    RECRUITING

    Changchun, Jilin, 215000, China

  • Jinan Central Hospital Affiliated to Shandong University

    RECRUITING

    Jinan, Shandong, China

  • Liaoning Cancer Hospital & Institute

    RECRUITING

    Shenyang, Liaoning, China

  • Linyi Cancer hospital

    RECRUITING

    Linyi, Shandong, China

  • Meizhou People's Hospital

    RECRUITING

    Meizhou, Guangdong, China

  • Peking University Third Hospital

    RECRUITING

    Beijing, Beijing Municipality, China

  • Shandong Cancer Hospital

    RECRUITING

    Jinan, Shandong, 250117, China

  • Shandong Cancer Hospital

    NOT_YET_RECRUITING

    Jinan, Shandong, China

  • Shandong Provincial Public Health Clinical Center

    NOT_YET_RECRUITING

    Jinan, Shandong, China

  • Shanghai General Hospital

    NOT_YET_RECRUITING

    Shanghai, Shanghai Municipality, China

  • Shanghai Ninth People's Hospital

    NOT_YET_RECRUITING

    Shanghai, Shanghai Municipality, China

  • Shanghai Pulmonary Hospital

    NOT_YET_RECRUITING

    Shanghai, Shanghai Municipality, China

  • Shantou University Medical College Tumour Hospital

    RECRUITING

    Shantou, Guangdong, China

  • Shanxi Province Cancer Hospital

    NOT_YET_RECRUITING

    Taiyuan, Shanxi, China

  • SiChuan Cancer Hospital

    NOT_YET_RECRUITING

    Chengdu, Sichuan, China

  • Sichuan Cancer Hospital

    RECRUITING

    Chengdu, Sichuan, China

  • Sun Yat-sen University Cancer Center

    NOT_YET_RECRUITING

    Guangzhou, Guangdong, China

  • Taizhou Hospital of Zhejiang

    RECRUITING

    Taizhou, Zhejiang, China

  • The Affiliated Cancer Hospital of Xinjiang Medical University

    NOT_YET_RECRUITING

    Ürümqi, Xinjiang, China

  • The Affiliated Hospital of NanChang University

    NOT_YET_RECRUITING

    Nanchang, Jiangxi, China

  • The Affiliated Hospital of Qingdao University

    RECRUITING

    Qingdao, Shandong, China

  • The Affiliated Hospital of Xuzhou medical University

    RECRUITING

    Xuzhou, Jiangsu, China

  • The Affiliated Huashan Hospital of Fudan University

    NOT_YET_RECRUITING

    Shanghai, Shanghai Municipality, China

  • The First Affiliated Hospital Of Henan University&Technology

    NOT_YET_RECRUITING

    Luoyang, Henan, China

  • The First Affiliated Hospital Of Xi'an JiaoTong University

    NOT_YET_RECRUITING

    Xian, Shanxi, China

  • The First Affiliated Hospital of Nanyang Medical College

    RECRUITING

    Nanyang, Henan, China

    Contact Email: •••••@•••••

  • The First Affiliated Hospital of Sun Yat-sen University

    RECRUITING

    Guangzhou, Guangdong, China

  • The First Affiliated Hospital of Zhengzhou University

    RECRUITING

    Zhengzhou, Henan, China

  • The First Hospital of China Medical University Physical Examination Center

    NOT_YET_RECRUITING

    Shenyang, Liaoning, China

  • The First Peoples Hospital of Jingzhou

    RECRUITING

    Jingzhou, Hubei, China

  • The No.10 Peoples Hospital

    RECRUITING

    Shanghai, Shanghai Municipality, China

  • The People's Hospital of Guangxi

    RECRUITING

    Nanning, Guangxi, China

  • The Second Affiliated Hospital of Chongqing Medical University

    NOT_YET_RECRUITING

    Chongqing, Chongqing Municipality, China

  • The Second Affiliated Hospital of Soochow University

    NOT_YET_RECRUITING

    Suzhou, Jiangsu, China

  • The Second Affiliated Hospital of Zhejiang University school of Medicine

    NOT_YET_RECRUITING

    Hangzhou, Zhejiang, China

  • The Second Hospital of Anhui Medical University

    NOT_YET_RECRUITING

    Hefei, Anhui, China

  • The Sixth Affiliated Hospital of Sun Yat-Sen University

    RECRUITING

    Guangzhou, Guangdong, China

  • The Third Hospital of Nanchang

    RECRUITING

    Nanchang, Jiangxi, China

  • The Third People's Hospital of Hunan Province

    RECRUITING

    Yueyang, Hunan, China

  • The first affiliated hospital of Anhui Medical University

    RECRUITING

    Hefei, Anhui, China

  • The first affiliated hospital of Chongqing Medical University

    NOT_YET_RECRUITING

    Chongqing, Chongqing Municipality, China

  • The second Hospital of Dalian Medical University

    NOT_YET_RECRUITING

    Dalian, Liaoning, China

    Contact Email: •••••@•••••

  • Tongji Hospital

    RECRUITING

    Wuhan, Hubei, China

  • Union Hospital Tongji Medical College HuaZhong University of Science Technology

    NOT_YET_RECRUITING

    Wuhan, Hubei, China

  • Union Hospital, Tongji Medical College,Huazhong University of Science and Technology

    RECRUITING

    Wuhan, Hubei, China

  • Weifang People's Hospital

    NOT_YET_RECRUITING

    Weifang, Shandong, China

  • West China Hospital of Sichuan University

    NOT_YET_RECRUITING

    Chengdu, Sichuan, China

  • West China Hospital,Sichuan Universtiy

    NOT_YET_RECRUITING

    Chengdu, Sichuan, China

  • Xiangya hospital Central South University

    RECRUITING

    Changsha, Hunan, China

  • Xiangyang Central Hospital

    NOT_YET_RECRUITING

    Xiangyang, Hubei, China

    Contact Email: •••••@•••••

  • Xinqiao Hospital

    RECRUITING

    Chongqing, Chongqing Municipality, China

  • Xinqiao Hospital of AMU

    RECRUITING

    Chongqing, Chongqing Municipality, China

  • Xinxiang Medical University No.1 Affiliated Hospital

    RECRUITING

    Xinxiang, Henan, China

  • Xuzhou Central Hospital

    RECRUITING

    Xuzhou, Jiangsu, China

  • Yiwu Central Hospital

    RECRUITING

    Jinhua, Zhejiang, China

  • Yunnan Tumor Hospital

    RECRUITING

    Kunming, Yunnan, China

  • ZheJiang Cancer Hospital

    NOT_YET_RECRUITING

    Hangzhou, Zhejiang, China

  • Zhejiang Province People's Hospital

    NOT_YET_RECRUITING

    Hangzhou, Zhejiang, China

  • Zhejiang Province People's Hospital

    RECRUITING

    Hangzhou, Zhejiang, China

  • Zhejiang University Medical College Affiliated No.1 Hospital

    RECRUITING

    Hangzhou, Zhejiang, China

  • Zhujiang Hospital of Southern Medical University

    NOT_YET_RECRUITING

    Guangzhou, Guangdong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.